Skip to main content

Advertisement

SpringerLink
Log in

VEGF Expression Predicts Survival in Patients with Peritoneal Surface Metastases from Mucinous Adenocarcinoma of the Appendix and Colon

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

High levels of vascular endothelial growth factor (VEGF) in ovarian cancer metastases are associated with a worse prognosis in patients treated with chemotherapy. VEGF-directed therapy improves survival for those with metastatic colorectal cancer. Patients with mucinous adenocarcinomas metastatic to the peritoneal surfaces can be treated with cytoreductive surgery, and both tumor grade and cytoreduction status are prognostic. We hypothesized that angiogenic indices may be prognostic in patients undergoing cytoreductive surgery for mucinous adenocarcinoma of the appendix and colon.

Methods

Cytoreductive cases from a 5-year period from the University of Cincinnati peritoneal malignancy database were reviewed. CD 34 counts (blood vessels) and VEGF expression was evaluated by means of immunohistochemistry on specimens from patients undergoing cytoreductive surgery and intraperitoneal hyperthermic perfusion (IPHP) for mucinous adenocarcinoma.

Results

A total of 26 males and 9 females, with a mean age of 50 years, underwent cytoreductive surgery and IPHP for mucinous adenocarcinoma of appendiceal (n = 32) or colonic (n = 3) origin. With a mean follow-up of 18 months (range 1–63 months), 23 had disease recurrence and 12 were alive without recurrence. The mean survival was 19 months (range 1–63 months). CD34 counts did not correlate with recurrence or survival; however, average VEGF counts correlated with survival (P = 0.017), and, for patients with recurrence, this correlation was stronger (P = 0.002).

Conclusions

These results suggest that markers of tumor angiogenesis may predict survival in patients with peritoneal surface metastases from mucinous adenocarcinoma. These findings provoke the hypothesis that antiangiogenic therapies may be effective in patients with this devastating disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

Reference

  1. Limber GK, King RE, Silverberg SG. Pseudomyxoma peritonaei: a report of ten cases. Ann Surg 1973; 178:587–93

    Article  PubMed  CAS  Google Scholar 

  2. Mann WJ Jr, Wagner J, Chumas J, Chalas E. The management of pseudomyxoma peritonei. Cancer 1990; 66:1636–40

    Article  PubMed  Google Scholar 

  3. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004; 240:278–85

    Article  PubMed  Google Scholar 

  4. Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219:112–9

    Article  PubMed  CAS  Google Scholar 

  5. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6:727–31

    Article  PubMed  CAS  Google Scholar 

  6. Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001; 27:239–43

    Article  PubMed  CAS  Google Scholar 

  7. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006; 7:69–76

    Article  PubMed  Google Scholar 

  8. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 2005; 241:300–8

    Article  PubMed  Google Scholar 

  9. Culliford AT,4th, Brooks AD, Sharma S, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001; 8:787–95

    Article  PubMed  Google Scholar 

  10. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001; 88:458–63

    Article  PubMed  CAS  Google Scholar 

  11. Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004; 11:393–8

    Article  PubMed  Google Scholar 

  12. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55:3964–8

    PubMed  CAS  Google Scholar 

  13. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132:541–6

    PubMed  CAS  Google Scholar 

  14. Shaheen RM, Tseng WW, Vellagas R, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol 2001; 18:221–6

    PubMed  CAS  Google Scholar 

  15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42

    Article  PubMed  CAS  Google Scholar 

  16. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000; 66:561–8

    PubMed  CAS  Google Scholar 

  17. Ahmad SA, Kim J, Sussman JJ, et al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 2004; 11:387–92

    Article  PubMed  Google Scholar 

  18. Ahmad SA, Liu W, Jung YD, et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001; 61:1255–9

    PubMed  CAS  Google Scholar 

  19. Takahashi Y, Bucana CD, Akagi Y, et al. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res 1998; 4:429–34

    PubMed  CAS  Google Scholar 

  20. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999; 6:373–8

    Article  PubMed  CAS  Google Scholar 

  21. Yoshikawa T, Tsuburaya A, Miyagi Y, et al. Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer. Anticancer Res 2006; 26:3849–53

    PubMed  CAS  Google Scholar 

  22. Osada R, Horiuchi A, Kikuchi N, et al. Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 2006; 37:1414–25

    Article  PubMed  CAS  Google Scholar 

  23. Gadducci A, Viacava P, Cosio S, et al. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res 2003; 23:3001–8

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, University of Cincinnati Medical Center, 234 Goodman St., ML #0772, Cincinnati, Ohio, 45219, USA

    Jocelyn M. Logan-Collins M.D, Andrew M. Lowy M.D, Toni M. Robinson-Smith M.D, Seena Kumar M.D, Jeffrey J. Sussman M.D, Laura E. James M.S & Syed A. Ahmad M.D

  2. Department of Pathology, University of Cincinnati Medical Center, Cincinnati, Ohio, USA

    Toni M. Robinson-Smith M.D & Seena Kumar M.D

Authors
  1. Jocelyn M. Logan-Collins M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew M. Lowy M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toni M. Robinson-Smith M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seena Kumar M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeffrey J. Sussman M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Laura E. James M.S
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Syed A. Ahmad M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Syed A. Ahmad M.D.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Logan-Collins, J.M., Lowy, A.M., Robinson-Smith, T.M. et al. VEGF Expression Predicts Survival in Patients with Peritoneal Surface Metastases from Mucinous Adenocarcinoma of the Appendix and Colon. Ann Surg Oncol 15, 738–744 (2008). https://doi.org/10.1245/s10434-007-9699-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-007-9699-7

Keywords

Search

Navigation